Rhode Island is a vital hub for New England's biomanufacturing industry, and we're excited to grow our presence in Smithfield.
We're expanding our legacy in regenerative medicine at 100 Technology Way, a cutting-edge biomanufacturing facility designed to support our industry-leading portfolio of advanced wound care products.
New England is our home, and our investment in Smithfield strengthens our ties to the region. We're driving economic growth, fostering collaboration, and creating exciting career opportunities in biotech, biomanufacturing, and research.
in annual statewide economic output
increase in Rhode Island's annual GDP
annual boost in state tax revenue
job-years created in construction & related industries
Our plans to resume commercial production of Dermagraft® begin at the cutting-edge facility at 100 Technology Way. Purpose-built for consistency, scale, and innovation, this new environment powers the next generation of our bioengineered healing solutions.
Relative increase in % of patients achieving complete DFU closure vs conventional therapy alone.1,2
Organogenesis Holdings Inc. is a leading regenerative medicine company developing, manufacturing, and commercializing advanced solutions for wound care, surgical applications, and sports medicine. We offer a comprehensive portfolio of innovative regenerative products that support patients across the continuum of care.
Organogenesis Smithfield will add manufacturing, R&D and logistics capabilities supporting existing and planned products designed to advance innovation and regenerative solutions
